Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H16N8 |
| Molecular Weight | 272.309 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1=NC(N)=C2N=C(N(C)C2=N1)N3N=CC=N3
InChI
InChIKey=CYYQMAWUIRPCNW-UHFFFAOYSA-N
InChI=1S/C12H16N8/c1-3-4-5-8-16-10(13)9-11(17-8)19(2)12(18-9)20-14-6-7-15-20/h6-7H,3-5H2,1-2H3,(H2,13,16,17)
| Molecular Formula | C12H16N8 |
| Molecular Weight | 272.309 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. | 2005 Nov 3 |
|
| ST 1535: a preferential A2A adenosine receptor antagonist. | 2006 Oct |
|
| The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. | 2006 Sep 28 |
|
| Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. | 2007 Aug |
|
| The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. | 2007 Feb 16 |
|
| Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. | 2007 Jul 2 |
|
| Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. | 2007 Nov |
|
| Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535. | 2008 Jan 28 |
|
| A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. | 2009 May |
|
| Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. | 2009 Nov |
|
| Direct B-alkyl Suzuki-Miyaura cross-coupling of 2-halopurines. Practical synthesis of ST1535, a potent adenosine A2A receptor antagonist. | 2010 Aug 6 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:32:30 UTC 2023
by
admin
on
Sat Dec 16 15:32:30 UTC 2023
|
| Record UNII |
NTK8WWM73W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
811021
Created by
admin on Sat Dec 16 15:32:30 UTC 2023 , Edited by admin on Sat Dec 16 15:32:30 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9860294
Created by
admin on Sat Dec 16 15:32:30 UTC 2023 , Edited by admin on Sat Dec 16 15:32:30 UTC 2023
|
PRIMARY | |||
|
496955-42-1
Created by
admin on Sat Dec 16 15:32:30 UTC 2023 , Edited by admin on Sat Dec 16 15:32:30 UTC 2023
|
PRIMARY | |||
|
NTK8WWM73W
Created by
admin on Sat Dec 16 15:32:30 UTC 2023 , Edited by admin on Sat Dec 16 15:32:30 UTC 2023
|
PRIMARY | |||
|
DTXSID60432000
Created by
admin on Sat Dec 16 15:32:30 UTC 2023 , Edited by admin on Sat Dec 16 15:32:30 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
